Anthea C Peters

List of Publications by Year
in descending order

38 papers	503 citations	840119 11 h-index	713013 21 g-index
38 all docs	38 docs citations	38 times ranked	892 citing authors

#	Article	IF	Citations
1	Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood, 2008, 112, 5171-5179.	0.6	82
2	The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years. Transplantation, 2018, 102, 1553-1562.	0.5	59
3	Mammalian DNA mismatch repair protects cells from UVB-induced DNA damage by facilitating apoptosis and p53 activation. DNA Repair, 2003, 2, 427-435.	1.3	50
4	Ineffectiveness of highâ€dose methotrexate for prevention of <scp>CNS</scp> relapse in diffuse large <scp>B</scp>â€cell lymphoma. American Journal of Hematology, 2021, 96, 764-771.	2.0	46
5	DNA Mismatch Repair Protein Msh6 Is Required for Optimal Levels of Ultraviolet-B-Induced Apoptosis in Primary Mouse Fibroblasts. Journal of Investigative Dermatology, 2003, 121, 876-880.	0.3	24
6	Epsteinâ€Barr virus associated smooth muscle tumors in solid organ transplant recipients: Incidence over 31Âyears at a single institution and review of the literature. Transplant Infectious Disease, 2019, 21, e13010.	0.7	24
7	Expanded antigen-experienced CD160⁺CD8⁺effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia. , 2021, 9, e002189.		23
8	Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders. World Journal of Gastrointestinal Pathophysiology, 2015, 6, 181.	0.5	19
9	Biological and clinical significance of GSK-3beta in mantle cell lymphoma--an immunohistochemical study. International Journal of Clinical and Experimental Pathology, 2010, 3, 244-53.	0.5	19
10	Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model. Cancers, 2018, 10, 206.	1.7	16
11	Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world. Leukemia and Lymphoma, 2019, 60, 133-141.	0.6	16
12	Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. Clinical Cancer Research, 2022, 28, 4003-4017.	3.2	15
13	DNA Instability and Human Disease. Molecular Diagnosis and Therapy, 2001, 1, 21-28.	3.3	12
14	Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score. Leukemia and Lymphoma, 2011, 52, 2124-2129.	0.6	12
15	Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphomaâ€type postâ€transplant lymphoproliferative disorder. British Journal of Haematology, 2020, 189, 97-105.	1.2	12
16	Autologous Stem Cell Transplantation Is a Curative Treatment Modality for Relapsed or Refractory Follicular Lymphoma, and Both Recent Rituximab Exposure and Follicular Lymphoma International Prognostic Index (FLIPI) 0â€“1 Scores Predict Improved Outcome. Blood, 2010, 116, 687-687.	0.6	9
17	Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 183-183.	0.6	8
18	Posttransplant Lymphoproliferative Disorder After Clinical Islet Transplantation: Report of the First Two Cases. American Journal of Transplantation, 2017, 17, 2474-2480.	2.6	7

#	Article	IF	Citations
19	Lack of Effectiveness of Intravenous High-Dose Methotrexate for Prevention of CNS Relapse in Patients with High-Risk DLBCL: A Retrospective Analysis from Alberta, Canada. Blood, 2020, 136, 26-27.	0.6	7
20	Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis. Biology of Blood and Marrow Transplantation, 2016, 22, 941-948.	2.0	6
21	IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia and Lymphoma, 2020, 61, 1653-1659.	0.6	6
22	The fludarabine, cytarabine, and granulocyte colonyâ€stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracyclineâ€based therapy for the treatment of acute myeloid leukemia for patients with preâ€existing cardiac disease. European Journal of Haematology, 2016, 97, 471-478.	1.1	5
23	Classic Hodgkin lymphoma post-transplant lymphoproliferative disorders (PTLD) are often preceded by discordant PTLD subtypes. Leukemia and Lymphoma, 2020, 61, 3319-3330.	0.6	5
24	Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities. Leukemia and Lymphoma, 2022, 63, 583-590.	0.6	5
25	Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid Leukemia. Leukemia Research, 2016, 45, 47-52.	0.4	4
26	Three-Dimensional Reconstructed Bone Marrow Matrix Culture Improves the Viability of Primary Myeloma Cells In-Vitro via a STAT3-Dependent Mechanism. Current Issues in Molecular Biology, 2021, 43, 313-323.	1.0	3
27	Epsteinâ€“Barr Virus Infection and Lymphoproliferative Disorders After Transplantation. , 2016, , 477-512.		2
28	The Adverse Consequences of Initial Watchful Waiting for Patients With Follicular Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 829-835.	0.2	2
29	Lymphopenia and EBER-Negativity Predict Poor Survival in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD) Treated in the Rituximab Era. Blood, 2011, 118, 1645-1645.	0.6	2
30	Gene Methylation and Silencing of WIF1 Is a Frequent Genetic Abnormality in Mantle Cell Lymphoma. International Journal of Molecular Sciences, 2021, 22, 893.	1.8	1
31	Epidemiology of Post-Transplant Lymphoproliferative Disorders in Children with Solid Organ Transplant over 34 Years of a Single Center Experience. Blood, 2019, 134, 1602-1602.	0.6	1
32	Tumor infiltrating lymphocytes predict survival in solid organ transplant recipients with monomorphic post-transplant lymphoproliferative disorders. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	1
33	Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy. Leukemia and Lymphoma, 2020, 61, 2492-2496.	0.6	0
34	Epigenetic Regulation of the WNT Canonical Pathway in Mantle Cell Lymphoma.. Blood, 2008, 112, 3340-3340.	0.6	0
35	Epidemiology Of Post-Transplant Lymphoproliferative Disorders Following Solid Organ Transplant In a Major Canadian Transplant Centre. Blood, 2013, 122, 4281-4281.	0.6	0
36	Morphologic Evolution in Post-Transplant Lymphoproliferative Disorders (PTLD): A Clinicopathologic Case Series. Blood, 2015, 126, 5008-5008.	0.6	0

#	Article	IF	Citations
37	CD3 T-Cell Infiltrates at Diagnosis Predicts Overall Survival in Solid Organ Transplant Recipients with Post-Transplant Lymphoproliferative Disorders (PTLD). Blood, 2016, 128, 1873-1873.	0.6	0
38	Tumor Lysis Syndrome: Incidence, Mitigation and Management in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice (DEVOTE) across Canada. Blood, 2021, 138, 3744-3744.	0.6	0